Electrochemical Aptamer-Based Sensors for Improved Therapeutic Drug Monitoring and High-Precision, Feedback-Controlled Drug Delivery

Dauphin‐Ducharme, Philippe; Yang, Kiyull; Arroyo‐Currás, Netzahualcóyotl; Ploense, Kyle L.; Zhang, Yameng; Gerson, Julian; Kurnik, Martin; Kippin, Tod E.; Stojanović, Milan N.

doi:10.1021/acssensors.9b01616

Cited by 172 publications

(267 citation statements)

References 53 publications

Supporting

Mentioning

249

Contrasting

Order By: Relevance

“…This study opened up the possibility of investigating interspecies metabolic differences and evaluating the effects of human-mimicked PK profiles on human diseases being studied in animal models. High-precision feedback control of vancomycin concentration in vivo was also achieved very recently, with defined plasma vancomycin rapidly achieved (∼30 min) and maintained at precise levels for over 5 h regardless of significant hour-to-hour changes in drug metabolism [ 89 ].…”

Section: In Vivo Biosensing Technologies For Continuous Drug Monitorimentioning

confidence: 99%

Towards wearable and implantable continuous drug monitoring: A review

Bian

Zhu

Rong

et al. 2021

Journal of Pharmaceutical Analysis

View full text Add to dashboard Cite

Continuous drug monitoring is a promising alternative to current therapeutic drug monitoring strategies and has strong potential to reshape our understanding of pharmacokinetic variability and to improve individualised therapy. This review highlights recent advances in biosensing technologies that support continuous drug monitoring in real time. We focus primarily on aptamer-based biosensors, wearable and implantable devices. Emphasis is given to the approaches employed in constructing biosensors. We pay attention to sensors’ biocompatibility, calibration performance, long-term characteristics stability and measurement quality. In the end, we discuss about the current challenges and issues to address in continuous drug monitoring to make it a promising, future tool for individualised therapy. The ongoing efforts are expected to result in fully integrated implantable drug biosensing technology. Thus, we may anticipate an era of advanced healthcare in which wearable and implantable biochips automatically adjust drug dosing in response to patient health conditions enabling the management of diseases and enhancing individualised therapy.

show abstract

Section: In Vivo Biosensing Technologies For Continuous Drug Monitorimentioning

confidence: 99%

Towards wearable and implantable continuous drug monitoring: A review

Bian

Zhu

Rong

et al. 2021

Journal of Pharmaceutical Analysis

View full text Add to dashboard Cite

show abstract

“…Such nanomaterials as silica and noble metal (Au, Ag, Pt, Pd) nanoparticles (NPs), graphene oxide (GO), and carbon nanotubes and their nanocomposites and nanohybrids, polymers and metal (Zn, Zr, Ce, Hf, Gd, Sn, Mn, Fe) oxides are actively used in the electrochemical aptasensor construction [ 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 ]. Electrochemical nanomaterial-based aptasensors are numerously reported in biomedical research [ 90 , 91 , 92 , 93 ] and may satisfy a huge demand for portable analytical devices with the selectivity and specificity sufficient for healthcare applications, such as POCT of biomarkers for chronic and emerging diseases: cancer, neurodegenerative disorders, cardiovascular diseases and chronic respiratory infections [ 94 ]. The unique properties of the aptamers stimulate the further development of innovative principles of such electrochemical aptasensor operation [ 95 , 96 ], and currently the electrochemical aptasensor-related articles represent ca.…”

Section: Electrochemical Aptasensorsmentioning

confidence: 99%

Design Strategies for Electrochemical Aptasensors for Cancer Diagnostic Devices

Malecka

Mikuła

Ferapontova

2021

Sensors

View full text Add to dashboard Cite

Improved outcomes for many types of cancer achieved during recent years is due, among other factors, to the earlier detection of tumours and the greater availability of screening tests. With this, non-invasive, fast and accurate diagnostic devices for cancer diagnosis strongly improve the quality of healthcare by delivering screening results in the most cost-effective and safe way. Biosensors for cancer diagnostics exploiting aptamers offer several important advantages over traditional antibodies-based assays, such as the in-vitro aptamer production, their inexpensive and easy chemical synthesis and modification, and excellent thermal stability. On the other hand, electrochemical biosensing approaches allow sensitive, accurate and inexpensive way of sensing, due to the rapid detection with lower costs, smaller equipment size and lower power requirements. This review presents an up-to-date assessment of the recent design strategies and analytical performance of the electrochemical aptamer-based biosensors for cancer diagnosis and their future perspectives in cancer diagnostics.

show abstract

“…Target binding alters the probability with which the reporter approaches the electrode, thus inducing a change in electron transfer rate that is easily measurable when the sensor is interrogated electrochemically. The resulting seconds‐resolved molecular measurements can be performed in complex clinical samples and even in situ in the living body, providing a convenient, highly‐time‐resolved window into physiological status or treatment state. Indeed, using their real‐time output it has even proven possible to perform closed loop feedback control over drug delivery, providing unprecedented precision in the maintenance of plasma drug levels in the middle of the therapeutic window …”

Section: Figurementioning

confidence: 99%

An Electrochemical Biosensor Architecture Based on Protein Folding Supports Direct Real‐Time Measurements in Whole Blood

2020

Self Cite

View full text Add to dashboard Cite

The ability to monitor drug and biomarker concentrations in the body with high frequency and in real time would revolutionize our understanding of biology and our capacity to personalize medicine. The few in vivo molecular sensors that currently exist, however, all rely on the specific chemical or enzymatic reactivity of their targets and thus are not generalizable. In response, we demonstrate here an electrochemical sensing architecture based on binding-induced protein folding that is 1) independent of the reactivity of its targets, 2) reagentless, real-time, and with a resolution of seconds, and 3) selective enough to deploy in undiluted bodily fluids. As a proof of principle, we use the SH3 domain from human Fyn kinase to build a sensor that discriminates between the proteins peptide targets and responds rapidly and quantitatively even when challenged in whole blood. The resulting sensor architecture could drastically expand the chemical space accessible to continuous, real-time biosensors.

show abstract

Electrochemical Aptamer-Based Sensors for Improved Therapeutic Drug Monitoring and High-Precision, Feedback-Controlled Drug Delivery

Cited by 172 publications

References 53 publications

Towards wearable and implantable continuous drug monitoring: A review

Towards wearable and implantable continuous drug monitoring: A review

Design Strategies for Electrochemical Aptasensors for Cancer Diagnostic Devices

An Electrochemical Biosensor Architecture Based on Protein Folding Supports Direct Real‐Time Measurements in Whole Blood

Contact Info

Product

Resources

About